This preprint is under consideration at Systematic Reviews. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Protocol
Ghodratollah Panahi
Tehran University of Medical Sciences
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8338-4633
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver disorders worldwide. In an aggressive type, non-alcoholic steatohepatitis (NASH) might lead to cirrhosis and hepatocellular carcinoma progression. Currently, there is no certified drug applied to treat NASH. Human studies have demonstrated the beneficial effects of probiotics supplementation in NAFLD. Due to the lack of appropriate studies and the emerging requirements for further illustration over the effects of probiotics on the treatment of NAFLD and NASH-related disorders in humans, in this study, we seek to evaluate this matter often papered over.
Methods: We will search PubMed, EMBASE, Cochrane Library, and Web of Science from inception to February 2021. Search terms are keywords and medical subject headings related to NAFLD, probiotics, glycemic indexes, inflammation, and dyslipidemia. 2 researchers will determine the search strategy after several pre-searches.
The Glycemic outcomes include glycated hemoglobin, fasting blood glucose, fasting insulin, homeostasis model assessment of insulin resistance.
The lipidomic outcomes include differences in High-density lipoprotein, Low-density lipoprotein, Total triglyceride, Total cholesterol.
The Inflammatory outcomes include differences in IL6, IL1β, TNFα, CRP.
The meta-analysis will be performed using END NOTE and STATA.
Results: Our study will systematically evaluate the effectiveness and safety of probiotics supplementation in NAFLD patients.
Conclusion: This study's results will give the proof for probiotics supplements in NAFLD treatment and provide an evidence for clinical treatment.
Keywords
Meta-Analysis, Systematic Review, Probiotic, NAFLD, Glycemic Index, Lipid Profiles, Inflammations
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 01 Mar, 2021
No community comments so far
Submission checks complete
On 23 Feb, 2021
First submitted
On 19 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
General Biochemistry
Learn more about our company.
This preprint is under consideration at Systematic Reviews. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Protocol
Ghodratollah Panahi
Tehran University of Medical Sciences
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8338-4633
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 01 Mar, 2021
No community comments so far
Submission checks complete
On 23 Feb, 2021
First submitted
On 19 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
General Biochemistry
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver disorders worldwide. In an aggressive type, non-alcoholic steatohepatitis (NASH) might lead to cirrhosis and hepatocellular carcinoma progression. Currently, there is no certified drug applied to treat NASH. Human studies have demonstrated the beneficial effects of probiotics supplementation in NAFLD. Due to the lack of appropriate studies and the emerging requirements for further illustration over the effects of probiotics on the treatment of NAFLD and NASH-related disorders in humans, in this study, we seek to evaluate this matter often papered over.
Methods: We will search PubMed, EMBASE, Cochrane Library, and Web of Science from inception to February 2021. Search terms are keywords and medical subject headings related to NAFLD, probiotics, glycemic indexes, inflammation, and dyslipidemia. 2 researchers will determine the search strategy after several pre-searches.
The Glycemic outcomes include glycated hemoglobin, fasting blood glucose, fasting insulin, homeostasis model assessment of insulin resistance.
The lipidomic outcomes include differences in High-density lipoprotein, Low-density lipoprotein, Total triglyceride, Total cholesterol.
The Inflammatory outcomes include differences in IL6, IL1β, TNFα, CRP.
The meta-analysis will be performed using END NOTE and STATA.
Results: Our study will systematically evaluate the effectiveness and safety of probiotics supplementation in NAFLD patients.
Conclusion: This study's results will give the proof for probiotics supplements in NAFLD treatment and provide an evidence for clinical treatment.
Figure 1
Loading...